Core Value Proposition

A. Comprehensive, Objective Dry Eye Screening

The screening pack combines:

• QuikVue– fast, easy tear film and lid margin evaluation that identifies dry eye signs

• MeiboVue– high-resolution meibomian gland imaging that objectively visualizes gland structure

Together they provide a complete dry eye assessment: tear function and gland anatomy — rather than symptom questionnaires alone. This improves diagnostic confidence and reduces missed cases.

Why this matters for a multi-clinic group:
Consistency and objectivity across locations. Providers get the same diagnostic baseline, reducing variability in clinical decisions.

Operational Efficiency Across a Group

A. Fast Throughput

Both devices are designed for quick data acquisition (typically under 2–3 minutes per eye), with minimal setup and operator training.

• Clinics can integrate them into routine refractions or annual exams

• No long appointment slots required

Result: Efficient patient flow even in high-volume practices.

B. Low Training Burden

• QuikVue is intuitive and largely automated

• MeiboVue requires minimal specialized training

This reduces onboarding time for staff and ensures cross-clinic standardization without heavy investment in technician certification.

Scalable Clinical Workflow

A. Standardized Protocol Across Clinics

A unified dry eye screening protocol enables:

• Same clinical steps at each location

• Comparable data collection

• Centralized training and quality assurance

This standardization facilitates group-wide clinical performance monitoring.

B. Data Integration for Enterprise Analytics

If integrated into EHR, this becomes a group-wide dry eye dataset supporting:

• Population health analysis

• Referral tracking

• Care pathway optimization

Such data is valuable for internal quality reviews and payer negotiations.

Improved Patient Experience and Retention

A. Faster, More Comfortable Screening

Patients appreciate quick, non-invasive imaging over lengthy traditional tests (e.g., Schirmer, fluorescein breakup without imaging). This increases attendees' satisfaction and trust.

B. Visual Evidence Drives Compliance

Seeing real images of their own meibomian glands or tear film gives patients:

• Immediate understanding of condition

• Motivation to accept further evaluation and treatment

This often leads to higher treatment acceptance and compliance.

Revenue and Practice Growth Impacts

A. Creates a Referral Engine

Offering modern dry eye screening differentiates the group from local competitors.

• Primary care referrals increase

• Patients seeking advanced dry eye assessment self-refer

This builds practice volume without additional marketing spend.

B. Drives Revenue Through Care Pathways

Once screened, patients move into:

• Targeted treatment plans

• Follow-up imaging

• Therapeutic procedures (e.g., IPL, thermal pulsation) as applicable

This extends lifetime patient value.

Modularity and Capital Efficiency

A. Flexible Deployment

Because the pack scales from a single station in small clinics to multiple units across a group, you can:

• Start with pilot deployment in high-volume sites

• Expand as ROI is proven

B. Lower Per-Clinic Cost vs Full Diagnostic Suites

Compared to high-end diagnostic towers or multi-modal tear labs, this pack:

• Has a lighter footprint

• Lower initial capital outlay

• Minimal maintenance burden

For a group with many locations, this improves capital efficiency.

Strategic Alignment for PE Optometry Groups

A. Supports Value-Based Care

Objective screening and measurable outcomes align with:

• Quality metrics

• Reimbursement frameworks

• Population health goals

B. Enhances Group Brand Positioning

Positioning the group as a dry eye care leader attracts:

• Referring optometrists and ophthalmologists

• Patients seeking specialized care

This builds long-term practice value.